Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. develops immuno-oncology therapies for cancer, with recurring updates centered on botensilimab (BOT) and balstilimab (BAL), its CTLA-4/PD-1 immunotherapy combination. Company news regularly covers clinical data in solid tumors, including metastatic colorectal cancer, melanoma and gastroesophageal cancer, as well as translational biomarker work and combination approaches that use antibody therapeutics, adoptive cell therapy through MiNK Therapeutics and adjuvants.
Agenus updates also address regulatory-authorized access pathways for BOT+BAL, including France's AAC framework and paid named-patient programs where permitted, along with financial results, equity financing activity, commercial readiness, manufacturing collaborations and corporate governance developments.
Agenus (Nasdaq: AGEN) appointed BAP Pharma as its exclusive global partner to coordinate access programs for botensilimab plus balstilimab (BOT+BAL).
BAP Pharma will manage France's government-reimbursed AAC pathway, paid named-patient programs in select countries, logistics, case coordination and payment processing. Agenus reported >270 physician inquiries from >30 countries and cites ongoing Phase 3 BATTMAN development.
Agenus (NASDAQ: AGEN) reported Phase II investigator-initiated data showing a 77% disease control rate (DCR) and long-term survival beyond 20 months in a subset of heavily pretreated PD-1 refractory gastroesophageal cancer patients.
Patients receiving an induction strategy had longer PFS (6.9 vs. 3.5 months; HR 0.19; p=0.015) and longer median OS (9.5 vs. 5.2 months), with 43% of induction-treated patients alive at 12 and 18 months. The study did not meet its primary ORR endpoint; safety was consistent with component agents.
Agenus (Nasdaq: AGEN) will present investigator‑initiated Phase II data of a novel triplet immunotherapy—botensilimab (BOT) + balstilimab (BAL) with agenT‑797—in PD‑1 refractory gastroesophageal cancer (GEC) at AACR 2026.
Presentation is April 20, 2026 (2:00–5:00 PM PT / 5:00–8:00 PM EDT), Poster Section 52, Abstract CT166. Data aim to inform immune modulation, sequencing, and durability of response in checkpoint‑refractory tumors.
Agenus (Nasdaq: AGEN) announced enrollment of the first patient in the global Phase 3 BATTMAN (CO.33) trial (NCT07152821) testing botensilimab (BOT) + balstilimab (BAL) versus best supportive care in refractory, unresectable MSS/pMMR metastatic colorectal cancer.
The registrational study plans to enroll approximately 830 patients across >100 sites in Canada, France, Australia and New Zealand through cooperative groups CCTG, GI Cancer Trials and PRODIGE.
Agenus (Nasdaq: AGEN) will host a stakeholder webcast on March 31, 2026 at 4:30 p.m. ET to review clinical progress of botensilimab + balstilimab (BOT+BAL), patient access programs, development across tumor types, and 2026 priorities. The session includes remarks by CEO Garo Armen and a live Q&A.
Speakers include the CEO, CMO Steven O’Day, and Head of Medical Affairs Kamel Djazouli; registration and question-submission links are provided for live participation.
Agenus (Nasdaq: AGEN) announced that preliminary Phase 2 results from an investigator-sponsored study of botensilimab (BOT) plus balstilimab (BAL) in first-line microsatellite stable metastatic colorectal cancer (MSS mCRC) will be presented at AACR 2026 (April 18–23) in San Diego.
The BBOpCo study (NCT06268015) evaluates BOT+BAL in MSS mCRC patients without liver, bone, or brain metastases, aiming to introduce immunotherapy earlier and reduce reliance on cytotoxic chemotherapy.
Agenus (Nasdaq: AGEN) reported 2025 results, recognizing initial $4.2M in pre-commercial BOT+BAL revenues from early access programs and initiating the global Phase 3 BATTMAN trial in refractory MSS metastatic colorectal cancer.
The company secured a $91M upfront collaboration with Zydus and triggered a $20M contingent payment to strengthen manufacturing and balance sheet.
Agenus (Nasdaq: AGEN) triggered a $20 million contingent payment under its collaboration with Zydus Lifesciences to fund contracted CMC and production work for botensilimab (BOT) and balstilimab (BAL). The activities support BLA/MAA readiness, expanded clinical and paid access supply, and U.S.-based manufacturing capacity.
Agenus (Nasdaq: AGEN) will release its Q4 and year-end 2025 financial results before the market opens on Monday, March 16, 2026. The company will host a stakeholder briefing webcast in late March to spotlight strategic plans, data milestones and updates on global botensilimab (BOT) and balstilimab (BAL) development.
Agenus (Nasdaq: AGEN) presented translational and clinical biomarker data from its Phase 1b C-800-01 trial of botensilimab (BOT) plus balstilimab (BAL) showing activity in immunologically “cold” tumors.
In 341 efficacy-evaluable patients (data cutoff Dec 13, 2025) overall response rate was 17%, clinical benefit rate 26%, median overall survival 17.2 months and 24‑month OS rate 38%. Integrated blood and tumor markers improved survival stratification (C‑index up to 0.73), particularly in MSS metastatic colorectal cancer.